Conference Reports for NATAP
December 4, 2011 - December 8, 2011
Kauai, HI, USA
Host targeting antiviral (HTA) alisporivir presents a high barrier to resistance both in vitro and in HCV patients with no cross-resistance to DAAs
Reported by Jules Levin
Kai Lin, Ph.D.
"Resistance is Futile" - a Satellite Mini-symposium at HepDART 2011 December 4th, 2011
In Vitro Assessment of Potential Drug-Drug Interactions Between Telaprevir and Cyclophilin Inhibitors in the Treatment of Chronic Hepatitis C